Current research paper describes highly specific and reproducible 1 order derivative spectroscopic method for quantitative analysis of Sitagliptin which is a DPP4 inhibitors Dapagliflozin SGLT2 from its synthetic mixture. Both drugs are Anti Diabetics class. Present analytical was developed on Shimadzu double beam spectrophotometer equipped with UV probe 2.42 as software using methyl alcohol so...

INTRODUCTION Sodium glucose cotransporter 2 (SGLT2) inhibitors are effective blood-glucose-lowering medications with beneficial effects on body weight in patients with type 2 diabetes mellitus (T2DM). However, observed weight loss is less than that predicted from quantified glycosuria, suggesting a compensatory increase in energy intake or a decrease in energy expenditure. Studies using dual-en...

OBJECTIVES This meta-analysis aimed to evaluate whether dapagliflozin is synergistic with other antidiabetic drugs without body weight gain. SETTING Randomised controlled trial (RCT) reports were retrieved from PubMed, Cochrane Library, EMBASE, ClinicalTrials.gov, Google Scholar and Google. Eligible RCTs were selected according to the criteria (including types of participants, intervention, o...

Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has been widely used in treatment of diabetic nephropathy (DN). Previous studies have shown that it both glucose-lowering effects and renoprotective functions DN. Tubulointerstitial fibrosis plays an important role the pathogenesis development progression Angiotensin‑converting enzyme (ACE2), major component renin-angiotensin sy...

INTRODUCTION To date there is a lack of economic analysis comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) to sodium-glucose co-transporter 2 inhibitors (SGLT-2i) for the treatment of type 2 diabetes mellitus (T2DM). Liraglutide and dapagliflozin are the most commonly prescribed GLP-1RA and SGLT-2i in the UK. This analysis investigated the cost-effectiveness of liraglutide 1.2 and...

The sodium-glucose cotransporter-2 (SGLT2) inhibitor group of drugs are now assuming an importance in the improvement cardiovascular outcomes a similar way that introduction HMG-CoA reductase inhibitors (statins) did 1990s. SGLT2 proteins on surface renal tubule cells responsible for 90% glucose re-absorption from glomerular filtrate with inhibition increasing loss both and sodium urine. modern...

Dapagliflozin which is also known as Farxiga in the US and Forxiga EU a drug was developed by Bristol-Myers Squibb partnership with Astra Zeneca. It available Oxra it marking Sun Pharmaceutical Industries Ltd. contains active substance second member of selective sodium glucose co-transporter-2 (SGLT-2) inhibitor first group among oral anti-diabetic agents are independent insulin secretion. The ...

Objective: Type 2 Diabetes mellitus (T2DM) and osteoporosis, which increase with age, are two common diseases different complications. The risk of fractures due to osteoporosis is 6 times higher in patients diabetes (DM). Medications used the treatment DM addition disease itself associated osteoporotic fractures. This study was planned examine effects pioglitazone dapagliflozin, T2DM, on develo...